# Reduced Dose Thrombolytic in Intermediate/High Risk Pulmonary Thromboembolism

> **NCT05512702** · — · UNKNOWN · sponsor: **Ege University** · enrollment: 100 (estimated)

## Conditions studied

- Pulmonary Embolism

## Interventions

- **DRUG:** Tissue Plasminogen Activator, Alteplase
- **DRUG:** Low-molecular weight heparin

## Key facts

- **NCT ID:** NCT05512702
- **Lead sponsor:** Ege University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-03
- **Primary completion:** 2023-06-03
- **Final completion:** 2024-06-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05512702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05512702, "Reduced Dose Thrombolytic in Intermediate/High Risk Pulmonary Thromboembolism". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05512702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*